Tuesday, June 1, 2021

Transcenta Announced Completion of First Patient Dosing in PET-CT Imaging Study of Radionuclide-Labeled CLDN18.2 Antibody

SUZHOU, China, June 1, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced completion of first patient dosing in PET-CT...



from PR Newswire: https://ift.tt/3wOIBhx

No comments:

Post a Comment